| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815929 | EPI HLTH | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Jan, 2024
(3 months from now) | |
| US8420688 | EPI HLTH | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Aug, 2024
(10 months from now) | |
| US7812049 | EPI HLTH | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
May, 2028
(4 years from now) | |
| US8883838 | EPI HLTH | Pharmaceutical cream compositions and methods of use |
Dec, 2031
(8 years from now) | |
| US11517560 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US9974773 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US10751325 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US10335391 | EPI HLTH | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
Rhofade is owned by Epi Hlth.
Rhofade contains Oxymetazoline Hydrochloride.
Rhofade has a total of 8 drug patents out of which 0 drug patents have expired.
Rhofade was authorised for market use on 18 January, 2017.
Rhofade is available in cream;topical dosage forms.
Rhofade can be used as once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, once daily topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream, where the patient experiences no rebound or worsening of facial erythema post-treatment, once daily topical treatment of persistent facial erythema associated with rosacea in adults, once daily topical treatment of persistent facial erythema associated with rosacea in female adults.
The generics of Rhofade are possible to be released after 11 June, 2035.
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with ...
Dosage: CREAM;TOPICAL
RHOFADE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic